Entropy Technologies LP Purchases 11,436 Shares of STERIS plc $STE

Entropy Technologies LP grew its position in STERIS plc (NYSE:STE) by 614.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,297 shares of the medical equipment provider’s stock after buying an additional 11,436 shares during the period. Entropy Technologies LP’s holdings in STERIS were worth $3,371,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Trust Co. of Vermont boosted its holdings in shares of STERIS by 30.2% in the 4th quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 38 shares in the last quarter. Bailard Inc. boosted its holdings in shares of STERIS by 3.5% in the 4th quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock valued at $283,000 after buying an additional 38 shares in the last quarter. Magnolia Capital Advisors LLC boosted its holdings in shares of STERIS by 1.2% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock valued at $888,000 after buying an additional 41 shares in the last quarter. Colonial Trust Co SC boosted its holdings in shares of STERIS by 0.3% in the 3rd quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after buying an additional 42 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in STERIS by 34.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 45 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Stock Down 0.0%

NYSE:STE opened at $207.50 on Monday. The company has a market cap of $20.25 billion, a PE ratio of 26.17 and a beta of 0.93. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $216.08 and its two-hundred day moving average is $237.20.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts anticipate that STERIS plc will post 11.18 EPS for the current year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s payout ratio is presently 31.78%.

Insider Activity at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the completion of the sale, the chief executive officer directly owned 63,647 shares in the company, valued at approximately $13,493,164. The trade was a 2.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the sale, the director owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. The trade was a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 5,909 shares of company stock valued at $1,257,083. Company insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $270.00 target price on shares of STERIS in a research report on Thursday, May 21st. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. KeyCorp dropped their target price on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.